Evidence map›Paper›PMID 41909839›Full record

ArticleFrontiers in cellular and infection microbiology2026

Repurposing approved drugs targeting

Yosser Zina Abdelkrim, Rafeh Oualha, Sonia Abbes, Isleme Khalfaoui, Thouraya Mejri, Mourad Barhoumi, Hela Abid, Emna Harigua-Souiai, Ikram Guizani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yosser Zina AbdelkrimLaboratory of Molecular Epidemiology and Experimental Pathology (LR11IPT04/LR16IPT04), Institut Pasteur de Tunis - University Tunis El Manar, Tunis, Tunisia.
Rafeh OualhaLaboratory of Molecular Epidemiology and Experimental Pathology (LR11IPT04/LR16IPT04), Institut Pasteur de Tunis - University Tunis El Manar, Tunis, Tunisia.
Sonia AbbesLaboratory of Molecular Epidemiology and Experimental Pathology (LR11IPT04/LR16IPT04), Institut Pasteur de Tunis - University Tunis El Manar, Tunis, Tunisia.
Isleme KhalfaouiLaboratory of Molecular Epidemiology and Experimental Pathology (LR11IPT04/LR16IPT04), Institut Pasteur de Tunis - University Tunis El Manar, Tunis, Tunisia.
Thouraya MejriLaboratory of Molecular Epidemiology and Experimental Pathology (LR11IPT04/LR16IPT04), Institut Pasteur de Tunis - University Tunis El Manar, Tunis, Tunisia.
Mourad BarhoumiLaboratory of Molecular Epidemiology and Experimental Pathology (LR11IPT04/LR16IPT04), Institut Pasteur de Tunis - University Tunis El Manar, Tunis, Tunisia.
Hela AbidLaboratory of Molecular Epidemiology and Experimental Pathology (LR11IPT04/LR16IPT04), Institut Pasteur de Tunis - University Tunis El Manar, Tunis, Tunisia.
Emna Harigua-SouiaiLaboratory of Molecular Epidemiology and Experimental Pathology (LR11IPT04/LR16IPT04), Institut Pasteur de Tunis - University Tunis El Manar, Tunis, Tunisia.
Ikram GuizaniLaboratory of Molecular Epidemiology and Experimental Pathology (LR11IPT04/LR16IPT04), Institut Pasteur de Tunis - University Tunis El Manar, Tunis, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Drug repurposing is a promising strategy for identifying new treatments against neglected tropical diseases such as leishmaniases, which are endemic in Asia, Africa, the Americas, and Southern Europe, offering the advantages of reduced development time and cost. In this context, computational and biochemical investigation of therapeutic targets plays a key role in guiding the selection of effective drug candidates. Methods: In this study, we investigated Results: Two compounds-Labetalol and Halofuginone-inhibited Discussion: This study confirms the

Indexed as

Antiprotozoal AgentsDrug RepositioningLeishmania infantumPurine-Nucleoside PhosphorylaseDrug Evaluation, PreclinicalEnzyme InhibitorsHumansInhibitory Concentration 50MacrophagesMolecular Docking Simulation5'-methylthioadenosine phosphorylaseAntiprotozoal AgentsEnzyme InhibitorsPurine-Nucleoside Phosphorylasedrug repurposinginfectious diseasesin vitro validationLabetalolLeishmania MTAPstructure-based drug discovery

Identifiers

PMID41909839
PMCPMC13021629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.